Inactive Instrument

News Neurometrix Inc Nasdaq

Equities

US6412555004

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Apr. 19	Sector Update: Health Care Stocks Advance Late Afternoon	MT
Apr. 19	Sector Update: Health Care Stocks Rise Friday Afternoon	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Advance Late Afternoon	Apr. 19	MT
Sector Update: Health Care Stocks Rise Friday Afternoon	Apr. 19	MT
NeuroMetrix Says Joshua Horowitz Joining Board, Terminates At-the-Market Equity Facility	Apr. 19	MT
NeuroMetrix Announces Steps Taken to Enhance Shareholder Value	Apr. 19	AQ
Neurometrix, Inc. Appoints Joshua S. Horowitz as a Class III director on the Board	Apr. 19	CI
Beyond the Pill: Athletes Champion PEMF and Non-Opioid Solutions for Pain Management (ENDV)	Mar. 20	AQ
NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy	Mar. 14	AQ
NeuroMetrix, Inc. Announces Publication of Study Demonstrating That DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy	Mar. 14	CI
NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® Fibromyalgia	Mar. 13	AQ
Ephraim Fields Discloses his Views on NeuroMetrix	Feb. 27	CI
RS Fund Discloses its Views on NeuroMetrix	Feb. 26	CI
Transcript : NeuroMetrix, Inc., Q4 2023 Earnings Call, Feb 22, 2024	Feb. 22
NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights	Feb. 22	AQ
NeuroMetrix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
NeuroMetrix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call	Feb. 15	AQ
NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value	Feb. 13	CI
NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value	Feb. 13	AQ
NeuroMetrix to Present at the Emerging Growth Conference on January 10, 2024	Jan. 08	AQ
NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)	Dec. 12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Neurometrix Inc Nasdaq

Equities

US6412555004

Summary

Filters